The reality is that, based on the Department of Health's response to the FoI on discussant presentations, the industry could rightly argue for the complete abolition of Public Summary Documents and against the release of any information they provide in submissions.

Latest Video
New Stories
-
Clinical trials: Competition across countries and companies
December 13, 2019 - - Latest News -
High in fees low on performance measures
December 13, 2019 - - Latest News -
Deborah Monk: Recollections from APMA to Medicines Australia
December 13, 2019 - - Latest News -
Novartis launches Innovation Prize with a focus on MS
December 13, 2019 - - Latest News -
New leadership for AbbVie Australia
December 12, 2019 - - Latest News -
Key trade agreement scraps pharma IP provision
December 12, 2019 - - Latest News -
Still time to take advantage of BioPharmaDispatch 2020 early registration
December 12, 2019 - - Latest News